HALF-YEAR REPORT 2019 Worldreginfo - F1b4840d-3Aaa-4093-82D3-3B7d6701d3b7

Total Page:16

File Type:pdf, Size:1020Kb

HALF-YEAR REPORT 2019 Worldreginfo - F1b4840d-3Aaa-4093-82D3-3B7d6701d3b7 VIFOR PHARMA HALF-YEAR REPORT 2019 WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 1 05.08.2019 13:10:48 PATIENTS AT OUR CORE About Andy Andy is a chef based in London with his wife Sarah and son Noah. He has lived with iron deficiency since being diagnosed at the age of 16. Despite living with iron deficiency and Crohn’s disease, he leads an active life and has a passion for food. He successfully competes at international cooking competitions. Andy recognises the signs and symptoms of iron deficiency and is able to proactively manage his iron levels with his physician, and the support of his wife. Today, Andy enjoys life without restrictions. WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 2 05.08.2019 13:10:51 TABLE OF CONTENTS 04 Letter to shareholders 27 2019 Outlook and financial guidance 06 Highlights 09 Vision, mission and strategy 28 Consolidated interim financial statements 10 Performance overview 30 Consolidated statement of income 31 Consolidated statement of 12 Our products comprehensive income Key growth drivers 32 Consolidated statement of financial position 14 Ferinject®/Injectafer® 33 Consolidated statement of changes in equity 18 Vifor Fresenius Medical Care Renal Pharma 34 Consolidated statement of cash flows 18 RENAL ANAEMIA MANAGEMENT 35 Notes to the consolidated financial statements 18 – Erythropoiesis-Stimulating Agents (ESAs) 18 – Mircera® 42 Upcoming dates 18 – Retacrit™ 43 Contact information 18 – Venofer® 19 – Vadadustat 19 MINERAL AND BONE MANAGEMENT 19 – Velphoro® 19 – Rayaldee® 20 KIDNEY FUNCTION PRESERVATION 20 – Avacopan 20 – CCX140 20 CONDITIONS ASSOCIATED WITH KIDNEY IMPAIRMENT AND ITS TREATMENT 20 – CR845 22 Veltassa® 24 Other products 24 – Maltofer® 24 – VIT-2763 25 OM PHARMA 25 – Broncho-Vaxom® 25 – Uro-Vaxom® 25 – Doxium® Vifor Pharma Ltd. Half-year Report 2019 3 WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 3 05.08.2019 13:10:51 LETTER TO SHAREHOLDERS Etienne Jornod Stefan Schulze DEAR SHAREHOLDER, Vifor Pharma Group achieved a strong financial 25% and 30%. The progress achieved in the first and operating performance in the first half of half of 2019 also makes us confident to achieve 2019, building on the outstanding progress made our Milestone 2020 targets of more than CHF 2 in 2018. Through sustained focus on the execu- billion net sales and EBITDA in the range of tion of our three strategic growth drivers, we are CHF 700 million. on track to deliver our ambitious financial and business goals, and to realise our vision of Each of our three growth drivers, Ferinject®/ becoming global leader in iron deficiency, Injectafer®, the joint company Vifor Fresenius nephrology and cardio-renal therapies. Medical Care Renal Pharma, and Veltassa® delivered a strong performance in H1 2019. It is now more than two years since we created Vifor Pharma as a stand-alone company. We are very happy to report that the positive momen- FERINJECT®/INJECTAFER® tum continued into 2019 and we are well posi- tioned to achieve our objectives for both the full Ferinject®/Injectafer® expanded its position as year 2019 and Milestone 2020. Furthermore the global leader in intravenous (i.v.) iron in value, we are increasingly focused on the goals of with strong growth particularly in the areas of Objective 2025. gastroenterology in the US, and in chronic heart failure and patient blood management in Europe. During the first half of 2019, Vifor Pharma Group By June 2019, the product was approved in 81 further expanded its global leadership position countries, with more than 10 million years of in iron deficiency and continued to move patient experience. We continue to expect full towards leadership in nephrology and cardio- year reported growth of approximately 20% and renal therapies. Total net sales increased by in-market sales for Ferinject®/Injectafer® of 22.2% to CHF 913.3 million, compared to prior more than CHF 1 billion for the full year 2019. year, and reported EBITDA was up 32.6% at CHF 254.6 million compared to CHF 192.0 million in H1 2018. VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) We have raised our full year guidance for 2019 with net sales expected to exceed 15% and The partnership with Fresenius Medical Care reported EBITDA expected to grow between through the joint company VFMCRP is the basis 4 Vifor Pharma Ltd. Half-year Report 2019 WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 4 05.08.2019 13:10:57 of our ambition to become the global leader imbursement negotiations and launches will in nephrology. The VFMCRP portfolio continued continue in line with individual reimbursement to grow in the first six months of 2019, due in timelines across Europe throughout 2019 and particular to the recent outstanding success of 2020. Veltassa® is on track to achieve growth in Velphoro® in the US. 2019 of approximately 50%. Mircera® also continued to perform strongly, We are investing in studies that demonstrate exceeding all expectations, primarily due to Veltassa®’s benefits to both patients and clini- the conversion of existing long-acting erythro- cians. Positive results from the phase-II AMBER poiesis-stimulating agent (ESA) patients within study were announced in May 2019, demonstrat- mid-sized and independent dialysis organisations ing Veltassa®’s potential to help patients with in the US. resistant hypertension and CKD to maintain optimal treatment. The DIAMOND study, evaluat- Venofer® maintained its position as the world’s ing the potential of Veltassa® in combination with leading i.v. iron brand in volume terms, with more renin-angiotensin-aldosterone system inhibitors than 25 million patient years of experience. (RAASi) medications to improve patient out- The publication of the PIVOTAL study results in comes, enrolled its first patient in May 2019. Q4 2018 helped to confirm the tolerability of Venofer® as a key differentiator, one of the main reasons the brand retains strong demand after FERROPORTIN many decades on the market. Vifor Pharma also made important progress with In April, we further expanded our partnership its own in-house developed product. In January, with Akebia in the US for vadadustat, creating we reported positive phase-I results from VIT-2763, an opportunity for it to be provided to up to 60% an oral ferroportin inhibitor, which aims to of US dialysis patients, subject to FDA approval. treat diseases related to iron overload. This has provided a strong basis for a phase-II study Velphoro® grew significantly in the US in the first planned to begin in the second half of 2019. half of 2019. This growth was driven by the update of the KDIGO (Kidney Disease Improving Global Outcomes) guidelines in 2017, to recommend the ORGANISATION use of non-calcium-based phosphate binders. The Board of Directors was further strengthened In May, our partner Cara Therapeutics, Inc. in May by the election of Dr Sue Mahony and announced positive results from the first US Kim Stratton to the Board of Directors. We would phase-III trial of CR845 in haemodialysis patients like to express our gratitude to Daniela Boss- with moderate-to-severe pruritus associated with hardt-Hengartner, Dr Sylvie Grégoire and Fritz chronic kidney disease (CKD). The results showed Hirsbrunner who stepped down after many statistically significant improvements in both the years of distinguished service. primary and secondary endpoints, with top-line results from a second global phase-III trial Our success in the first half of 2019 was made expected in H2 2019. possible due to the support of our shareholders and dedicated, talented employees across Vifor Pharma Group, who continue to deliver our VELTASSA® company mission – helping patients around the world with severe and chronic diseases, lead Veltassa®, our third strategic growth driver, better, healthier lives. continued to transform the treatment of patients with hyperkalaemia in the first half of the year. By Yours sincerely, the end of June, Veltassa® had been prescribed to over 100,000 patients since launch in the US, and is among the fastest growing nephrology drugs in the last ten years. In May 2019, the Act on the Reform of the Market Etienne Jornod Stefan Schulze for Medicinal Products (AMNOG) process Executive Chairman of President of the for Veltassa® in Germany was completed, with the Board of Directors Executive Committee Veltassa® now fully reimbursed. Further re- and COO Vifor Pharma Ltd. Half-year Report 2019 5 WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 5 05.08.2019 13:10:57 HIGHLIGHTS NET SALES MILLION CHF 913.3+22.2% EBITDA MILLION CHF 254.6+32.6% CORE EARNINGS¹ CASH FLOW FROM PER SHARE OPERATING ACTIVITIES EQUITY RATIO 2.11 CHF 197.9 MILLION CHF 74.0% –20.7% +159.6 million CHF –0.8 p.p. 1 Core earnings are defined as reported earnings after minorities adjusted for proportionate amortisation of intangible assets. 6 Vifor Pharma Ltd. Half-year Report 2019 WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 6 05.08.2019 13:10:57 TOTAL FERINJECT®/ INJECTAFER® NET SALES MILLION CHF 273.4+19.4% MIRCERA® NET SALES MILLION CHF 276.2+29.0% VELTASSA® NET SALES MILLION CHF 62.6+69.9% Vifor Pharma Ltd. Half-year Report 2019 7 WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 7 05.08.2019 13:10:57 8 Vifor Pharma Ltd. Half-year Report 2019 WorldReginfo - f1b4840d-3aaa-4093-82d3-3b7d6701d3b7 Half Year Report 2019_English_1 8 05.08.2019 13:10:58 VISION, MISSION AND STRATEGY Our vision To be global leader in iron deficiency, nephrology and cardio-renal therapies. The partner of choice for specialty pharmaceuticals and innovative, patient-focused solutions. Our mission We strive to help patients around the world with severe and chronic diseases lead better, healthier lives.
Recommended publications
  • How to Take Your Phosphate Binders
    How to take your phosphate binders Information for renal patients Oxford Kidney Unit Page 2 What are phosphate binders? To reduce the amount of phosphate you absorb from your food you may have been prescribed a medicine called a phosphate binder. Phosphate binders work by binding (attaching) to some of the phosphate in food. This will reduce the amount of phosphate being absorbed into your blood stream. A list of phosphate binders and how to take them is shown below. Phosphate binder How to take it Calcichew (calcium carbonate) Chew thoroughly 10-15 minutes before or immediately before food Renacet (calcium acetate) Phosex (calcium acetate) Osvaren (calcium acetate and magnesium carbonate) Swallow whole after the first Renagel 2-3 mouthfuls of food (sevelemer hydrochloride) Renvela tablets (sevelemer carbonate) Alucaps (aluminium hydroxide) Renvela powder Dissolve in 60ml of water and (sevelemer carbonate) take after the first 2-3 mouthfuls of food Fosrenol tablets Chew thoroughly towards the (lanthanum carbonate) end/immediately after each meal Fosrenol powder Mix with a small amount of (lanthanum carbonate) food and eat immediately Velphoro Chew thoroughly after the first (sucroferric oxyhydroxide) 2-3 mouthfuls The phosphate binder you have been prescribed is: ……………………………………………………………………………………………………………………………………………………….. Page 3 How many phosphate binders should I take? You should follow the dose that has been prescribed for you. Your renal dietitian can advise how best to match your phosphate binders to your meal pattern, as well as which snacks require a phosphate binder. What happens if I forget to take my phosphate binder? For best results, phosphate binders should be taken as instructed.
    [Show full text]
  • Renal Diet for Patients with Diabetes
    Webinar: BDA - Diabetes Specialist Group Renal diet for Patients with Diabetes By Gabby Ramlan Diabetes & Renal Specialist Dietitian Overview • Diabetes Dietitian Vs Renal Dietitian • Problems in individual with kidney disease • Salt • Protein • Phosphate • Potassium • Acute Kidney Injury (AKI) Around 40% people with diabetes eventually develop diabetic nephropathy or diabetes kidney disease. Diabetes is a leading cause of kidney failure in UK – around 20% starting dialysis have diabetes. Kidney Research UK “Dietary requirements for patients with both diabetes and chronic kidney disease (CKD) is more complicated than with each individual condition as it involves multiple nutrients” National Kidney Foundation (NKF) 2007 Diabetes vs Renal Specialist Dietitian Diabetes Renal • Salt • Salt • Lipid control • Lipid control • Carbohydrates • Protein • Glycaemic control • Potassium • OHAs • Fluid • Injectable meds • CKD-MBD • Insulin • Phosphate Binders • Vit D / calcimimetic Kidney’s Functions • Regulation of the composition and volume of body fluids – Na+, K+, Phosphate, Mg – Acid/base balance – BP & volume via renin angiotensin system • Excretion of waste products – Urea (protein metabolism) – Creatinine (muscle metabolism) – Drugs & toxins Kidney’s Fx • Endocrine fx - Erythropoetin & Hb • Metabolic - Control calcium/phosphate/ PTH balance - Vit D metabolism - Excretion of phosphate Common problems with renal patients • Anaemia – no dietary advice CKD – Mineral Bone Disorder (MBD) 1. Vitamin D Fluid Hyperkalaemia 2. Corrected Hypertension 1.
    [Show full text]
  • ACC.Org/Infographics ©2020 American College of Cardiology W20006
    Potassium Binders in the Management of Chronic Hyperkalemia ✖ Development of hyperkalemia can be either acute or chronic depending on the time of onset, the presence or absence of symptoms, and underlying etiology. ✖ Chronic hyperkalemia is a potentially life-threatening condition commonly seen in older patients with heart failure (HF), chronic kidney disease (CKD), and renin-angiotensin- aldosterone system (RAAS) inhibitor therapy. PROBLEM ✖ Although sodium polystyrene sulfonate (Kayexalate®) is widely used for hyperkalemia management, its use has many limitations including: - A lack of robust randomized clinical trials showing evidence for efficacy and safety2 - An association with serious gastrointestinal (GI) injury (e.g. intestinal necrosis)2,5 - Limited use in patients with sodium intake restrictions3 ✔ Prior to initiating potassium binders, patients should be on a low potassium diet and treated with a potassium-wasting diuretic if appropriate. A dose adjustment of RAAS inhibitor therapies should be attempted in patients with CKD. ✔ Newer potassium binders, patiromer and sodium zirconium cyclosilicate, have more robust clinical trials documenting improved safety profile by reducing serum potassium and SOLUTION maintaining normokalemia in patients with HF and CKD.1,6,8,9 - RAAS inhibitors were able to be continued in patients with HF and CKD when receiving concurrent patiromer1,6,9 - Normokalemia was maintained in CKD patients with and without RAAS inhibitors therapy while receiving concurrent sodium zirconium cyclosilicate8 TREATMENT TABLE: Drug Name Patiromer Sodium zirconium cyclosilicate Binds potassium in lumen of GI and increases its fecal excretion Mechanism of Action Colon Small and large intestine Initial dose: 10 grams 3x daily for up to 48hrs 8.4 grams daily Maintenance dose: 10 grams daily Dosing Up-titrate at weekly intervals to reach Up-titrate at weekly intervals by 5 grams desired serum potassium concentration daily to reach desired serum potassium (max.
    [Show full text]
  • New Brunswick Drug Plans Formulary
    New Brunswick Drug Plans Formulary August 2019 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick TABLE OF CONTENTS Page Introduction.............................................................................................................................................I New Brunswick Drug Plans....................................................................................................................II Exclusions............................................................................................................................................IV Legend..................................................................................................................................................V Anatomical Therapeutic Chemical (ATC) Classification of Drugs A Alimentary Tract and Metabolism 1 B Blood and Blood Forming Organs 23 C Cardiovascular System 31 D Dermatologicals 81 G Genito Urinary System and Sex Hormones 89 H Systemic Hormonal Preparations excluding Sex Hormones 100 J Antiinfectives for Systemic Use 107 L Antineoplastic and Immunomodulating Agents 129 M Musculo-Skeletal System 147 N Nervous System 156 P Antiparasitic Products, Insecticides and Repellants 223 R Respiratory System 225 S Sensory Organs 234 V Various 240 Appendices I-A Abbreviations of Dosage forms.....................................................................A - 1 I-B Abbreviations of Routes................................................................................A - 4 I-C Abbreviations of Units...................................................................................A
    [Show full text]
  • Hyperphosphataemia in Adults with Chronic Kidney Disease on Dialysis: Sucroferric Oxyhydroxide
    pat hways Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide Evidence summary Published: 6 January 2015 nice.org.uk/guidance/esnm51 Key points from the evidence The content of this evidence summary was up-to-date in January 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Sucroferric oxyhydroxide (Velphoro) is an iron-based phosphate binder. In 1 open-label, randomised controlled trial (RCT), sucroferric oxyhydroxide at a mean dose of 1500 mg iron (3 tablets) per day was non-inferior to sevelamer carbonate at a mean dose of 6.4 g (8 tablets) per day for lowering phosphate levels in adults with chronic kidney disease (CKD) who were on haemodialysis or peritoneal dialysis. More people in the sucroferric oxyhydroxide group withdrew from the study because of adverse events. The most common adverse events with sucroferric oxyhydroxide were gastrointestinal, particularly diarrhoea and discoloured faeces. Regulatory status: Sucroferric oxyhydroxide (Velphoro) is the first iron-based phosphate binder to be licensed in Europe for the control of serum phosphate levels in adults with CKD who are on haemodialysis or peritoneal dialysis. It was launched in the UK in January 2015. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 22 Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51) Effectiveness Safety Sucroferric oxyhydroxide Sucroferric oxyhydroxide is contraindicated in people with at a mean dose of haemochromatosis and any other iron accumulation 1500 mg (3 tablets) per disorder.
    [Show full text]
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database
    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
    [Show full text]
  • Assessment Report
    17 September 2020 EMA/522604/2020 Corr.1 Committee for Medicinal Products for Human Use (CHMP) Assessment report Velphoro Common name: sucroferric oxyhydroxide Procedure No. EMEA/H/C/002705/X/0020/G Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us An agency of the European Union Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.2. Epidemiology and risk factors, screening tools/prevention ...................................... 8 2.1.3. Biologic features ...............................................................................................
    [Show full text]
  • Pharmacology
    Pharmacology The current treatment of hyperkalemia in the emergency department (ED) varies considerably because of limited data on the efficacy of available agents [1]. A recent Cochrane review highlighted the limitations of the available studies [2], however, the United Kingdom Renal Association has developed clinical practice guidelines for the treatment of acute hyperkalemia [3]. Following are the commonly used agents for the treatment of hyperkalemia in the emergent setting. A threefold approach is currently adopted by clinicians: 1. Stabilization of the cardiac membranes 2. Redistribution of potassium 3. Elimination of potassium Stabilization of the Cardiac membranes Calcium The effect of potassium on myocytes is counter- balanced by the concurrent calcium concentration such that intravenous calcium antagonizes hyperkalemia induced cardiac membrane excitability and protects the heart against arrhythmias [4]. It is usually effective within minutes, as noted by an improvement in the ECG appearance or reversal of ECG abnormality. It is generally accepted that intravenous (IV) calcium is indicated for potentially life-threatening ECG changes (absent P waves, wide QRS, sine-wave pattern) [2] [5] [6], arrhythmias, or cardiac arrest [7]. The recommended dose of calcium salts ranges from 1000 – 3000 mg of calcium gluconate (10 - 30 mL of a 10% solution) or 500 -1000 mg of calcium chloride (5- 10 mL of a 10% solution) [5] [8]. The dose can be repeated if there is no effect within 5-10 minutes. Some adverse effects of intravenous calcium are peripheral vasodilation, hypotension, bradycardia, and arrhythmias [9]. A more serious adverse effect of IV calcium is tissue necrosis if extravasation occurs. This can be avoided if calcium gluconate is used, which is considered less toxic on peripheral veins.
    [Show full text]
  • Drug–Drug Interactions Between Sucroferric Oxyhydroxide and Losartan, Furosemide, Omeprazole, Digoxin and Warfarin in Healthy Subjects
    J Nephrol DOI 10.1007/s40620-014-0080-1 ORIGINAL ARTICLE Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects Edward Chong • Veena Kalia • Sandra Willsie • Peter Winkle Received: 1 November 2013 / Accepted: 8 March 2014 Ó The Author(s) 2014. This article is published with open access at Springerlink.com Abstract which AUC 0–8 h was measured), was unaffected to a Background The novel iron-based phosphate binder su- clinically significant extent by the presence of sucroferric croferric oxyhydroxide is being investigated for the treatment oxyhydroxide, irrespective of whether sucroferric oxyhy- of hyperphosphatemia. Patients with chronic kidney disease droxide was administered with the drug or 2 h earlier. often have multiple comorbidities that may necessitate the Conclusions There is a low risk of drug–drug interactions daily use of several types of medication. Therefore, the between sucroferric oxyhydroxide and losartan, furose- potential pharmacokinetic drug–drug interactions between mide, digoxin and warfarin. There is also a low risk of sucroferric oxyhydroxide and selected drugs commonly taken drug–drug interaction with omeprazole (based on AUC0–? by dialysis patients were investigated. values). Therefore, sucroferric oxyhydroxide may be Methods Five Phase I, single-center, open-label, random- administered concomitantly without the need to adjust the ized, three-period crossover studies in healthy volunteers dosage regimens of these drugs. investigated the effect of a single dose of sucroferric oxyhy- droxide 1 g (based on iron content) on the pharmacokinetics Keywords Chronic kidney disease Á of losartan 100 mg, furosemide 40 mg, omeprazole 40 mg, Hyperphosphatemia Á Sucroferric oxyhydroxide Á digoxin 0.5 mg and warfarin 10 mg.
    [Show full text]
  • Dorset Medicines Advisory Group
    Dorset Medicines Advisory Group SHARED CARE GUIDELINE FOR THE USE OF PHOSPHATE BINDERS IN THE MANAGEMENT OF HYPERPHOSPHATAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE. INDICATION This document provides guidance for the prescribing of phosphate binders for the management of hyperphosphatemia in patients receiving haemodialysis or peritoneal dialysis and patients with chronic kidney disease stage 4 or 5 who are not receiving dialysis. This shared care guideline covers adult patients under the care of the Dorset Renal Unit. Patients with chronic renal failure have reduced ability to excrete phosphate. Phosphate accumulation enhances parathyroid activity and leads to the calcification of arteries, significantly contributing to the excess cardiovascular morbidity in these patients, especially in younger age groups. Adequate control of serum phosphate levels is thought to be beneficial for the prevention of vascular and cardiac calcification in patients with renal failure and control of parathyroid hormone. A number of oral phosphate binders are available which may be used in the context of a multiple therapeutic approach. These include calcium acetate, calcium carbonate, calcium acetate/magnesium carbonate, lanthanum, sevelamer and sucroferric oxyhydroxide. These products may be used in combination with 1-hydroxycholecalciferol (alfacalcidol) or one of its analogues and/or cinacalcet to control the development of secondary hyperparathyroidism and renal bone disease. A calcium-based phosphate binder is generally used as the initial phosphate binder therapy for the treatment for hyperphosphatemia. Calcium acetate is preferred over calcium carbonate due to its lower elemental calcium content for the equivalent phosphate binding capacity, however patient preference in formulation should be taken into consideration. A non-calcium-based phosphate binder should be used in patients who cannot tolerate a calcium-based phosphate binder, whose serum calcium exceeds 2.5mmol/L or whose parathyroid levels are less than 15pmol/L.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Safety and Tolerability of the Potassium Binder Patiromer from a Global Pharmacovigilance Database Collected Over 4 Years Compar
    Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program Patrick Rossignol, Lea David, Christine Chan, Ansgar Conrad, Matthew Weir To cite this version: Patrick Rossignol, Lea David, Christine Chan, Ansgar Conrad, Matthew Weir. Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program. Drugs - real world outcomes, 2021, 10.1007/s40801-021-00254-7. hal-03236228 HAL Id: hal-03236228 https://hal.univ-lorraine.fr/hal-03236228 Submitted on 26 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Drugs - Real World Outcomes https://doi.org/10.1007/s40801-021-00254-7 ORIGINAL RESEARCH ARTICLE Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program Patrick Rossignol1,2 · Lea David3 · Christine Chan3 · Ansgar Conrad3 · Matthew R. Weir4 Accepted: 22 April 2021 © The Author(s) 2021 Abstract Introduction The availability of the sodium-free potassium binder patiromer opens new opportunities for hyperkalemia management.
    [Show full text]